Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07252739 · ClinicalTrials.gov registry record · Phase 2
KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
A Phase 2 study of Malignant Neoplasm, sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 130
- Enrollment target
- 13
- Study locations
NCT07252739 is a Phase 2 study of Malignant Neoplasm that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 130 participants, below the 511-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (75% lower). The trial reports 13 study locations across 10 states.
The verdict
NCT07252739, a Phase 2 study of Malignant Neoplasm, is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 130 participants
- Enrollment target
- 13
- Study locations
Study Summary
Researchers want to learn if using a study medicine called MK-1084 can help treat NSCLC. MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Carboplatin
- DRUG Pemetrexed
- BIOLOGICAL Cetuximab
- DRUG MK-1084
Study Locations (13)
Other
- Severance Hospital Yonsei University Health System ( Site 0080) - Seoul
- Hacettepe Universite Hastaneleri ( Site 0140) - Ankara
- VISION PARTNER Medical Centre ( Site 0135) - Kyiv
- LIMITED LIABILITY COMPANY "MEDICAL CENTER "DOBROBUT-CLINIC" ( Site 0138) - Kyiv
Florida
- Clermont Oncology Center ( Site 0041) - Clermont
Overijssel
- Deventer Ziekenhuis ( Site 0272) - Deventer
Cherkasy Oblast
- COMMUNAL NONPROFIT ENTERPRISE CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 0139) - Cherkasy
Dnipropetrovsk Oblast
- Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 0465) - Kryvyi Rih
Ivano-Frankivsk Oblast
- Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 0132) - Ivano-Frankivsk
Kirovohrad Oblast
- Limited Liability Company Ukrainian Center of Tomotherapy-Department of Chemotherapy ( Site 0467) - Kropyvnytskyi
Lviv Oblast
- Lviv Territorial Medical Union Multidisciplinary Clinical Hospital ( Site 0133) - Lviv
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2025-12-19 |
| Est. Completion | 2033-01-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07252739
The ClinicalTrials.gov registry entry for NCT07252739 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 511-participant average among 59 other Malignant Neoplasm trials with a reported enrollment target (75% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Malignant Neoplasm appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT07252739 reports 13 study locations spanning 10 distinct geographic areas - top geographies include Other, Florida, Overijssel.
Frequently Asked Questions
What is clinical trial NCT07252739 about?
NCT07252739 is a clinical study titled "KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)". Researchers want to learn if using a study medicine called MK-1084 can help treat NSCLC. MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how ...
What is the current status of trial NCT07252739?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 130 participants. The study started on 2025-12-19. Estimated completion is 2033-01-14.
What conditions does trial NCT07252739 study?
This clinical trial studies the following conditions: Malignant Neoplasm.
What interventions are being tested in trial NCT07252739?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Pemetrexed (DRUG), Cetuximab (BIOLOGICAL), MK-1084 (DRUG).
Who is sponsoring clinical trial NCT07252739?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07252739 being conducted?
This trial has 13 study locations across Florida, Overijssel, Cherkasy Oblast, Dnipropetrovsk Oblast, Ivano-Frankivsk Oblast. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus
RECRUITING · Phase 2
-
Intraoperative Tumor Margin Identification With ICG Dye Imaging
RECRUITING · Phase 2
-
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)
RECRUITING · Phase 2
-
Dexamethasone in Controlling Dyspnea in Patients With Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies
ACTIVE NOT RECRUITING · Phase 2
-
Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.